GRAIL, LLC
1525 O'Brien Drive
Menlo Park
California
94025
United States
Tel: 833-694-2553
Website: https://grail.com/
Email: customerservice@grail.com
About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
LEADERSHIP:
CEO: Bob Ragusa
101 articles about GRAIL, LLC
-
GRAIL To Initiate REACH Study To Evaluate Clinical Impact Of GalleriⓇ Multi-Cancer Early Detection (MCED) Test Among The Medicare Population
11/20/2023
GRAIL, LLC announced that it will initiate Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity following the U.S. Food and Drug Administration’s approval of GRAIL’s Investigational Device Exemption application and the Centers for Medicare and Medicaid Services’ approval for Medicare coverage of the study.
-
Research associates are always in demand. Check out these top companies currently hiring RAs.
-
October saw a surge of life science job activity with job applications up 65% from last year as well as a number of a significant layoff announcements.
-
The European Commission on Thursday ordered Illumina to divest Grail, opening the next chapter in the years-long regulatory saga. Illumina is reviewing the order, Reuters reported.
-
Whitman-Walker Institute, Cancer Support Community and GRAIL Collaborate On Research Aimed at Advancing Health Equity in Cancer Screening and Care Through Multi-Cancer Early Detection
8/23/2023
Whitman-Walker Institute, Cancer Support Community, and GRAIL, LLC announced a research collaboration aimed at advancing health equity in cancer screening and care with GalleriⓇ, a multi-cancer early detection test, in diverse patient populations.
-
Francis deSouza resigned from Illumina’s helm after strong campaigning from activist investor Carl Icahn and the ongoing regulatory roadblocks facing the company's acquisition of GRAIL.
-
New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing
6/3/2023
GRAIL, LLC announced results from a retrospective analysis of the interventional PATHFINDER study to assess whether diagnostic evaluations of individuals who received a cancer signal detected result with the Galleri® multi-cancer early detection test were appropriately directed by the test’s cancer signal origin predictions.
-
GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting
6/3/2023
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced data evaluating the Galleri® multi-cancer early detection test’s ability to detect a cancer signal and predict the cancer signal origin in asymptomatic individuals in the real-world setting.
-
Grail Expands Blood Test to Symptomatic Patients, Aims to Revolutionize Cancer Diagnosis
6/2/2023
-
GRAIL Presents Positive Analytical Validation Data on its Methylation-Based Post-Diagnostic Cancer Research Solution at American Association for Cancer Research (AACR) Annual Meeting 2023
4/19/2023
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today presented analytical validation data on its recently launched methylation-based post-diagnosis solution to accelerate cancer research (abstract LB297).
-
GRAIL Showcases Methylation Platform Performance Across Cancer Continuum With New Data at American Association for Cancer Research (AACR) Annual Meeting
4/11/2023
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, will present new data showcasing the performance of its methylation platform to detect cancer across the early- and post-diagnosis settings at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14-19, 2023.
-
Grail Introduces State-of-the-Art Methylation-Based Solution to Accelerate Cancer Research in the Post-Diagnosis Setting
1/9/2023
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced the availability of a state-of-the-art research use only offering for biopharmaceutical companies.
-
In a recent BioSpace poll, more than half of employers indicated they planned to continue recruiting employees remotely. We highlight just some of those jobs here.
-
It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.
-
GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
9/11/2022
GRAIL, LLC announced final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer.
-
CORRECTING and REPLACING GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
9/11/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced final results from the interventional PATHFINDER study, which evaluated multi-cancer early detection screening using a blood test and the clinical care pathways following a “cancer signal detected” MCED test result in 6,662 individuals aged 50 years or older, an age group at elevated risk for cancer.
-
The Administrative Law Judge overseeing the FTC’s challenge of Illumina’s acquisition of Grail rejected the regulator’s anti-competition argument, Illumina announced Thursday.
-
Grail and National Health Service (NHS) England Complete Enrollment of 140,000 Participants in Largest Study of Multi-Cancer Early Detection Test
7/18/2022
GRAIL, LLC announced today that the NHS-Galleri trial successfully completed enrollment in just over 10 months.
-
GRAIL and Ochsner Health Launch New Initiatives to Improve Cancer Detection Rates in Louisiana
6/3/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, and Ochsner Health announced a multi-faceted partnership to improve cancer detection rates in Louisiana using Galleri®, GRAIL’s multi-cancer early detection blood test.
-
GRAIL Announces Strategic Collaboration With AstraZeneca to Develop Companion Diagnostic Tests to Enable the Treatment of Early-Stage Cancer
6/2/2022
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced a broad strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s therapies.